Tracers / [177Lu]Lu-DTPA-PODSAJICAP-5B1
[177Lu]Lu-DTPA-PODSAJICAP-5B1
Also written as [Lu-177]Lu-DTPA-PODSAJICAP-5B1
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Radioimmunoconjugate (site-specifically modified anti-CA19-9 monoclonal antibody 5B1 with CHX-A″-DTPA chelator)
- Target / mechanism
- CA19-9 antigen targeting via antibody 5B1 PMID 40782054
- Clinical application
- Pancreatic cancer (CA19-9-expressing, e.g., BxPC3 xenograft model) PMID 40782054
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | >95% | >99% | DTPA-PODSAJICAP-5B1 | 40782054 2025 Bioconjug Chem The radiolabeling of each of the immunoconjugates with [177Lu]Lu3+ was performed according to standard protocols — was isolated in >95% radiochemical yield, >99% purity, and a specific activity of ∼ 5 mCi/mg |
Need this precursor?We can point you to suppliers for [177Lu]Lu-DTPA-PODSAJICAP-5B1, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40782054. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40782054: 'DTPA-PODSAJICAP-5B1 in ∼ 65% yield from the parental mAb'.